{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:42:58Z","timestamp":1783446178884,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic macular oedema (DMO) is a common cause of vision loss and blindness. To inform the 2024 UK NICE guideline for treating people with centre-involving DMO (CI-DMO) and central retinal thickness (CRT) of \u2265400\u2009\u00b5m, the cost-effectiveness of various anti-vascular endothelial growth factor (anti-VEGF) and macular laser treatments was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A de novo Markov model evaluated the lifetime costs and quality-adjusted life-years (QALYs) of various anti-VEGFs (aflibercept, bevacizumab, brolucizumab, faricimab, ranibizumab and ranibizumab biosimilar), macular lasers (standard threshold laser and subthreshold micropulse laser), and some treatment combinations from the perspective of the\u00a0UK NHS. The model included eight health states defined by best-corrected visual acuity ranging between &gt;85 and \u226425 letters. The model\u2019s inputs were derived from published literature, while an original network meta-analysis of several clinical trials informed visual outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All anti-VEGFs demonstrated greater clinical effectiveness and produced more QALYs (ranging from 9.211 to 9.271) than both types of macular lasers (8.928 and 8.944), but lasers were the most cost-effective due to their substantially lower costs. Using confidential price discounts, ranibizumab biosimilar (Ongavia) and brolucizumab had ICERs below \u00a320,000 per QALY, while aflibercept, ranibizumab (Lucentis) and faricimab had ICERs below \u00a325,000 per QALY, compared to no treatment. Bevacizumab was the most cost-effective anti-VEGF treatment due to its significantly lower cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given their clinical and cost-effectiveness at confidential prices, NICE recommends offering a licensed cost-effective anti-VEGF as first-line treatment for people with CI-DMO and CRT\u2009\u2265\u2009400\u2009\u00b5m. The use of bevacizumab for this population is not licensed in the UK and would be considered off-label.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04015-6","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:30:08Z","timestamp":1758277808000},"page":"2963-2972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of anti-vascular endothelial growth factor and macular laser treatments for people with centre-involving diabetic macular oedema and central retinal thickness of at least 400 micrometres"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2131-6243","authenticated-orcid":false,"given":"Kirsty","family":"Luckham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Tebbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Dadswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Yosef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole","family":"Taske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip I.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-4771","authenticated-orcid":false,"given":"Christiana","family":"Dinah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2666-2937","authenticated-orcid":false,"given":"Noemi","family":"Lois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-3392","authenticated-orcid":false,"given":"Syed","family":"Mohiuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"4015_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:1\u201325.","journal-title":"Eye Vis"},{"key":"4015_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","volume":"34","author":"WM Amoaku","year":"2020","unstructured":"Amoaku WM, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey L, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye. 2020;34:1\u201351.","journal-title":"Eye"},{"key":"4015_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00417-008-0960-y","volume":"247","author":"E Davidov","year":"2009","unstructured":"Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M. Diabetic retinopathy and health-related quality of life. Graefe\u2019s Arch Clin Exp Ophthalmol. 2009;247:267\u201372.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4015_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/bjo.2007.122416","volume":"92","author":"SM Hariprasad","year":"2008","unstructured":"Hariprasad SM, Mieler W, Grassi M, Green J, Jager R, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008;92:89\u201392.","journal-title":"Br J Ophthalmol"},{"key":"4015_CR5","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1185\/03007995.2010.482503","volume":"26","author":"E Chen","year":"2010","unstructured":"Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26:1587\u201397.","journal-title":"Curr Med Res Opin"},{"key":"4015_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2022.08.012","volume":"130","author":"N Lois","year":"2023","unstructured":"Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, et al. Diabetic macular edema and diode subthreshold micropulse laser: a randomized double-masked noninferiority clinical trial. Ophthalmology. 2023;130:14\u201327.","journal-title":"Ophthalmology"},{"key":"4015_CR7","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/eye.2014.264","volume":"28","author":"A Mansouri","year":"2014","unstructured":"Mansouri A, Sampat K, Malik K, Steiner J, Glaser B. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye. 2014;28:1418\u201324.","journal-title":"Eye"},{"key":"4015_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Aflibercept for treating diabetic macular oedema. Technology appraisal guidance TA346. 2015 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta346."},{"key":"4015_CR9","unstructured":"National Institute for Health and Care Excellence (NICE). Brolucizumab for treating diabetic macular oedema. Technology appraisal guidance TA820. 2022 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta820."},{"key":"4015_CR10","unstructured":"National Institute for Health and Care Excellence (NICE). Faricimab for treating diabetic macular oedema. Technology appraisal guidance TA799. 2022 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta799."},{"key":"4015_CR11","unstructured":"National Institute for Health and Care Excellence (NICE). Ranibizumab for treating diabetic macular oedema. Technology appraisal guidance TA274. 2013 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta274."},{"key":"4015_CR12","doi-asserted-by":"crossref","unstructured":"Luckham K, Tebbs H, Claxton L, Burgess P, Dinah C, Lois N, et al. A Markov model assessing the cost-effectiveness of various anti-vascular endothelial growth factor drugs and panretinal photocoagulation for the treatment of proliferative diabetic retinopathy. Eye. 2025;39:1364\u201372.","DOI":"10.1038\/s41433-025-03641-4"},{"key":"4015_CR13","doi-asserted-by":"crossref","unstructured":"Simmonds M, Llewellyn A, Walker R, Fulbright H, Walton M, Hodgson R, et al. Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis. Health Technol Assess. 2024;23:1\u201371.","DOI":"10.3310\/PCGV5709"},{"key":"4015_CR14","unstructured":"National Institute for Health and Care Excellence (NICE). Diabetic retinopathy: management and monitoring. NICE guideline NG242. 2024 [Available from: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ng10256."},{"key":"4015_CR15","unstructured":"National Institute for Health and Clinical Excellence (NICE). Developing NICE guidelines: the manual. NICE process and methods PMG20. 2024 [Available from: https:\/\/www.nice.org.uk\/process\/pmg20."},{"key":"4015_CR16","doi-asserted-by":"publisher","unstructured":"Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Systemat Rev. 2014;10. https:\/\/doi.org\/10.1002\/14651858.CD007419.pub4.","DOI":"10.1002\/14651858.CD007419.pub4"},{"key":"4015_CR17","unstructured":"National Institute for Health and Care Excellence (NICE). Dexamethasone intravitreal implant for treating diabetic macular oedema. Technology appraisal guidance TA824. 2022 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta824."},{"key":"4015_CR18","unstructured":"National Institute for Health and Care Excellence (NICE). Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy. Technology appraisal guidance TA301. 2013 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta301."},{"key":"4015_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/bjophthalmol-2011-300726","volume":"96","author":"P Mitchell","year":"2012","unstructured":"Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96:688\u201393.","journal-title":"Br J Ophthalmol"},{"key":"4015_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3111\/13696998.2016.1154566","volume":"19","author":"J Haig","year":"2016","unstructured":"Haig J, Barbeau M, Ferreira A. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema. J Med Econ. 2016;19:663\u201371.","journal-title":"J Med Econ"},{"key":"4015_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-018-3804-4","volume":"19","author":"M Pochopien","year":"2019","unstructured":"Pochopien M, Beiderbeck A, McEwan P, Zur R, Toumi M, Aball\u00e9a S. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN\u00ae) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. BMC Health Serv Res. 2019;19:1\u201314.","journal-title":"BMC Health Serv Res"},{"key":"4015_CR22","doi-asserted-by":"crossref","unstructured":"R\u00e9gnier SA, Malcolm W, Haig J, Xue W. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective. Clinicoecon Outcomes Res. 2015;7:235\u201347.","DOI":"10.2147\/CEOR.S82556"},{"key":"4015_CR23","unstructured":"National Institute for Health and Care Excellence (NICE). Evidence reviews for the effectiveness and acceptability of intravitreal steroids, macular laser and anti-vascular endothelial growth factor agents for treating diabetic macular oedema. NICE guideline NG242. 2024 [Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/ https:\/\/www.nice.org.uk\/guidance\/ng242\/evidence\/g-effectiveness-and-acceptability-of-intravitreal-steroids-macular-laser-and-antivascular-endothelial-growth-factor-agents-for-treating-diabetic-macular-oedema-pdf-13490775475."},{"key":"4015_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40273-016-0459-z","volume":"35","author":"L Claxton","year":"2017","unstructured":"Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R. Simulation modelling in ophthalmology: application to cost effectiveness of ranibizumab and aflibercept for the treatment of wet age-related macular degeneration in the United Kingdom. Pharmacoeconomics. 2017;35:237\u201348.","journal-title":"Pharmacoeconomics"},{"key":"4015_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/SZKI2484","volume":"26","author":"N Lois","year":"2022","unstructured":"Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, et al. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT. Health Technol Assess. 2022;26:1.","journal-title":"Health Technol Assess"},{"key":"4015_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/bjophthalmol-2017-310941","volume":"102","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Ou WC, Khurana RN, Brown DM, Clark WL, Boyer DS. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br J Ophthalmol. 2018;102:631\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4015_CR27","unstructured":"Office for National Statistics. National life tables\u2013life expectancy in the UK: 2018 to 2020 2021 [Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2018to2020."},{"key":"4015_CR28","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCULATIONAHA.108.829176","volume":"119","author":"SR Preis","year":"2009","unstructured":"Preis SR, Hwang S-J, Coady S, Pencina MJ, D\u2019Agostino SrRB, Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119:1728\u201335.","journal-title":"Circulation"},{"key":"4015_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1524-4733.2009.00527.x","volume":"12","author":"C Czoski-Murray","year":"2009","unstructured":"Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009;12:793\u20139.","journal-title":"Value Health"},{"key":"4015_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","volume":"117","author":"NM Bressler","year":"2010","unstructured":"Bressler NM, Chang TS, Su\u00f1er IJ, Fine JT, Dolan CM, Ward J, et al. Vision-related function after ranibizumab treatment by better-or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010;117:747\u201356. e4.","journal-title":"Ophthalmology"},{"key":"4015_CR31","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.4103\/ijo.IJO_3066_21","volume":"70","author":"N Dhingra","year":"2022","unstructured":"Dhingra N, Upasani D, Ghanchi FD. Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Indian J Ophthalmol. 2022;70:2065\u201370.","journal-title":"Indian J Ophthalmol"},{"key":"4015_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105:216\u201321.","journal-title":"Br J Ophthalmol"},{"key":"4015_CR33","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41433-020-1048-0","volume":"35","author":"C Kern","year":"2021","unstructured":"Kern C, Fu DJ, Huemer J, Faes L, Wagner SK, Kortuem K, et al. An open-source data set of anti-VEGF therapy in diabetic macular oedema patients over 4 years and their visual acuity outcomes. Eye. 2021;35:1354\u201364.","journal-title":"Eye"},{"key":"4015_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40258-014-0098-5","volume":"12","author":"S Mohiuddin","year":"2014","unstructured":"Mohiuddin S. A systematic and critical review of model-based economic evaluations of pharmacotherapeutics in patients with bipolar disorder. Appl Health Econ Health Policy. 2014;12:359\u201372.","journal-title":"Appl Health Econ Health Policy"},{"key":"4015_CR35","doi-asserted-by":"publisher","first-page":"e015007","DOI":"10.1136\/bmjopen-2016-015007","volume":"7","author":"S Mohiuddin","year":"2017","unstructured":"Mohiuddin S, Busby J, Savovi\u0107 J, Richards A, Northstone K, Hollingworth W, et al. Patient flow within UK emergency departments: a systematic review of the use of computer simulation modelling methods. BMJ Open. 2017;7:e015007.","journal-title":"BMJ Open"},{"key":"4015_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00055735-200006000-00004","volume":"11","author":"S Sharma","year":"2000","unstructured":"Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol. 2000;11:175\u20139.","journal-title":"Curr Opin Ophthalmol"},{"key":"4015_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/jamaophthalmol.2022.6142","volume":"141","author":"DW Hutton","year":"2023","unstructured":"Hutton DW, Glassman AR, Liu D, Sun JK, Network DR, Sneath M, et al. Cost-effectiveness of aflibercept monotherapy vs bevacizumab first followed by aflibercept if needed for diabetic macular edema. JAMA Ophthalmol. 2023;141:268\u201374.","journal-title":"JAMA Ophthalmol"},{"key":"4015_CR38","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.ophtha.2015.03.032","volume":"122","author":"GC Brown","year":"2015","unstructured":"Brown GC, Brown MM, Turpcu A, Rajput Y. The cost-effectiveness of ranibizumab for the treatment of diabetic macular edema. Ophthalmology. 2015;122:1416\u201325.","journal-title":"Ophthalmology"},{"key":"4015_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/13696998.2019.1666855","volume":"23","author":"N Holekamp","year":"2020","unstructured":"Holekamp N, Duff SB, Rajput Y, Garmo V. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. J Med Econ. 2020;23:287\u201396.","journal-title":"J Med Econ"},{"key":"4015_CR40","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.ophtha.2013.02.002","volume":"120","author":"JD Stein","year":"2013","unstructured":"Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013;120:1835\u201342.","journal-title":"Ophthalmology"},{"key":"4015_CR41","unstructured":"National Institute for Health and Clinical Excellence (NICE). Aflibercept solution for injection for treating wet age\u2011related macular degeneration. Technology appraisal guidance TA294. 2013 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta294."},{"key":"4015_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19740","volume":"19","author":"PH Scanlon","year":"2015","unstructured":"Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess. 2015;19:1\u2013116.","journal-title":"Health Technol Assess"},{"key":"4015_CR43","unstructured":"National Institute for Health and Care Excellence (NICE). Age-related macular degeneration. NICE guideline NG82. 2018 [Available from: https:\/\/www.nice.org.uk\/guidance\/ng82."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04015-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:07:09Z","timestamp":1762171629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04015-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":43,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4015"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04015-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}